

Date: 18<sup>th</sup> January, 2024

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001  
Scrip Code:533573

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.  
'Exchange Plaza', Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: APLLTD

Dear Sir/Madam,

**Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Pursuant to Regulation 30 of the SEBI Listing Regulations, 2015, this is to inform the exchange that the Company has agreed to invest USD 1.0 million in the form of Promissory notes issued by RIGImmune, Inc. where the Company is an existing shareholder.

The details as required under Regulation 30 of SEBI (Listing obligations and Disclosure requirements) Regulations, 2015 are enclosed herewith and marked as Annexure – 'A'.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Alembic Pharmaceuticals Limited**

**Manisha Saraf**  
**Company Secretary**

Encl: A/a

**ALEMBIC PHARMACEUTICALS LIMITED**

**Annexure – ‘A’**

Details as required under Regulation 30 of SEBI Listing Regulations read with Circular no SEBI/HO/CFD-PoD-1/P/CIR2023/123 dated 13<sup>th</sup> July 2023:

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	RIGImmune, Inc., USA Start-up entity.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms length”	No.
3.	Industry to which the entity being acquired belongs	Research and experimental development of new chemical entities (Drug development).
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	This investment will help the Company to get into niche segment of new chemical entities.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No.
6.	Indicative time period for completion of the acquisition	N.A.
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration.
8.	Cost of acquisition or the price at which the shares are acquired	N.A.
9.	Percentage of shareholding / control acquired and / or number of shares acquired	Pursuant to the investment made / to be made by the Company along with other third parties, the Company would hold 12.282% of Total Capital of the Target entity, post the above referred investment.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Research and experimental development of new chemical entities (Drug development) in USA.  Incorporated in 2020 Turnover Details*: 2020: NIL 2021: NIL 2022: USD 2.00 Million * Financials of 2023 is under preparation as they follows calendar year as their accounting year.

**ALEMBIC PHARMACEUTICALS LIMITED**